David A. Ramsay has been appointed chief financial officer at Halozyme Therapeutics, Inc. Mr. Ramsay most recently served as vice president of corporate development.   Mr. Ramsay joined the company in 2003 and his accomplishments include spearheading the process of taking Halozyme public in 2004, negotiating equity investments made by Roche and Baxter, negotiating and signing the Baxter Hylenex collaboration, and ultimately leading the effort to reintroduce Hylenex to the market in late 2011. Pr...